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Background: Prostate cancer (PCa), a highly incident and heterogeneous malignancy, mostly affects men from
developed countries. Increased knowledge of the biological mechanisms underlying PCa onset and progression
are critical for improved clinical management. MicroRNAs (miRNAs) deregulation is common in human cancers,
and understanding how it impacts in PCa is of major importance. MiRNAs are mostly downregulated in cancer,
although some are overexpressed, playing a critical role in tumor initiation and progression. We aimed to identify
miRNAs overexpressed in PCa and subsequently determine its impact in tumorigenesis.
Results: MicroRNA expression profiling in primary PCa and morphological normal prostate (MNPT) tissues
identified 17 miRNAs significantly overexpressed in PCa. Expression of three miRNAs, not previously associated
with PCa, was subsequently assessed in large independent sets of primary tumors, in which miR-182 and miR-375 were
validated, but not miR-32. Significantly higher expression levels of miR-375 were depicted in patients with higher
Gleason score and more advanced pathological stage, as well as with regional lymph nodes metastases. Forced
expression of miR-375 in PC-3 cells, which display the lowest miR-375 levels among PCa cell lines, increased apoptosis
and reduced invasion ability and cell viability. Intriguingly, in 22Rv1 cells, which displayed the highest miR-375
expression, knockdown experiments also attenuated the malignant phenotype. Gene ontology analysis implicated
miR-375 in several key pathways deregulated in PCa, including cell cycle and cell differentiation. Moreover, CCND2
was identified as putative miR-375 target in PCa, confirmed by luciferase assay.
Conclusions: A dual role for miR-375 in prostate cancer progression is suggested, highlighting the importance of
cellular context on microRNA targeting.
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Prostate cancer (PCa), the second most incident cancer
in men worldwide (31.1%) [1] and ranking first in inci-
dence in the US (27%) [2], is very heterogeneous, ran-
ging from clinical indolent to extremely aggressive
disease, causing substantial morbidity and mortality [3].
Adequate management is, thus, mandatory to avoid
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article, unless otherwise stated.on the other. A better understanding of the biological
mechanisms underlying PCa onset and progression are
likely to contribute to improved clinical and therapeutic
management.
Over the last two decades, deregulation of epigenetic
mechanisms has emerged as a relevant driving force in
PCa [4], with recent emphasis in altered microRNAs
(miRNAs) expression [5]. MicroRNAs are a class of
small non-coding RNAs, approximately 22 nucleotides
in length [6], highly conserved along the evolutionary
chain, with tissue and developmental stage-specific ex-
pression [7]. Currently, more than 2,000 human miR-
NAs are registered in the miRBase [8] and thought to
negatively regulate gene translation, thus decreasing
gene expression, and have been extensively implicated
in several crucial cellular pathways, such as apoptosis,Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 List of overexpressed microRNAs in low-density
miRNA RT-qPCR analysis (fold variation represents median
values for PCa vs. MNPT)
MicroRNA Fold variation (PCa vs. MNPT)
miR-449a# 3.92
miR-32 3.49
miR-548c-5p 2.71
miR-562 2.56
miR-103-as 2.53
miR-512-3p 2.41
miR-200c* 2.33
miR-147b 2.24
miR-770-5p 2.09
miR-518c* 2.00
miR-517b 1.88
miR-182 1.79
miR-615-3p 1.70
miR-496 1.59
miR-1200 1.58
miR-375 1.54
miR-551a 1.53
*Passanger strand. #Already studied in other work by our research group.
MNPT, morphological normal prostate; PCa, prostate cancer. In italics are the
microRNAs chosen for further validation.
Table 2 Clinical and pathological data of patients
included in miR-375 validation
Clinicopathological data Tumors (n = 114) MNPT (n = 15)
Age (years), median (range) 65 (49 to 74) 64 (45 to 80)
PSA (ng/mL), median (range) 8.00 (2.66 to 20.00) n.a.
Pathological stage, n (%)
pT2 58 (38.7%) n.a.
pT3a 24 (16.0%) n.a.
pT3b 33 (21.3%) n.a.
Gleason score, n (%)
<7 28 (18.7%) n.a.
=7 73 (48.7%) n.a.
>7 13 (8.7%) n.a.
n.a., not applicable; MNPT, morphological normal prostate.
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single miRNA might have multiple targets, and a single
mRNA may be targeted by several miRNAs [10].
In cancer, miRNAs are globally downregulated, although
some are notoriously upregulated [11]. Such trend has
been found in PCa, but most studies limit their analysis to
expression array results, based on few tumor samples, and
generally lacking subsequent validation in larger and inde-
pendent datasets [5,12]. This may, at the least partially, ex-
plain contradictory results in the literature, making it
difficult to establish specific PCa miRNA signatures [13].
Thus, assessing miRNAs differential expression in a robust
cohort of patients carrying primary tumors and searching
for miRNAs targets are critical to investigate its relevance
in PCa initiation and progression.
In this study, we sought to discover miRNAs upregulated
in PCa and unveil its role in prostate carcinogenesis
through modulation of miRNAs expression and identifica-
tion of putative molecular targets. Using a customized,
commercially available, platform, a small set of miRNAs
upregulated in PCa was identified, some of which have
been previously reported. Validation in two large independ-
ent sets of patients demonstrated that miR-375 expression
was increased in PCa with higher Gleason score and more
advanced pathological stage, which entail worse prognosis.
Following validation in clinical samples, miR-375 was also
found to be upregulated in PCa cell lines compared to
RWPE-1 (a benign prostate epithelial cell line). Modulation
of miR-375 expression in two PCa cell lines (22Rv1 and
PC-3) showed that this miRNA is involved in regulation of
cell viability and apoptosis, in a cell-context-dependent
manner. Furthermore, using a custom gene panel to search
for potential targets followed by specific luciferase assay val-
idation, CCND2 was identified and confirmed as miR-375
target in PCa. Our observations thus suggest that miR-375
overexpression may contribute to prostate carcinogenesis
and disease progression.
Results
MicroRNAs expression in prostate cancer tissues
Global expression of miRNAs was initially assessed and
compared in ten PCa and four morphological normal pros-
tate (MNPT) samples. Global miRNAs downregulation was
found in PCa, although overexpression, with fold variation
higher than 1.5, was depicted for 17 miRNAs (Table 1).
Among these, those previously associated with PCa in the
literature were excluded from further analysis, and the re-
mainders were further selected for validation in a large
sample set, and the respective clinical and pathological
characteristics are provided in Table 2 (Additional file 1:
Table S1). No significant differences in age were apparent
between the two groups. Because several miRNAs were
below detection level in quantitative reverse transcription-
polymerase chain reaction (RT-qPCR) analyses (probablydue to low expression levels), only three miRNAs
(miR-32, miR-182, and miR-375) were assessed in the
larger dataset. Whereas miR-182 and miR-375 were
significantly overexpressed in PCa (P < 0.001 for both),
confirming the results of the array, no significant dif-
ferences were found for miR-32 expression between PCa
and MNPT (Figure 1A and Additional file 2: Figure S1).
MiR-375 expression levels were significantly higher in cases
with higher Gleason score and more advanced pathological
stage at diagnosis (P < 0.05, P < 0.001, Figure 1B, C).
A B
C
Figure 1 Expression levels of miR-375 in PCa and normal prostate tissues (A), according to Gleason Score (B) and pathologic stage (C).
***P < 0.001; *P < 0.05.
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patients from The Cancer Genome Atlas
Further validation of the array results was performed
in a larger and independent dataset, that is, the miR-
NAseq expression data from PCa patients and matched
normal samples deposited in The Cancer Genome Atlas
(TCGA) (n = 326 and n = 50, respectively). Strikingly,
miR-375 was significantly overexpressed in all tumors com-
pared to matched normal samples (P < 0.0001; Figure 2A),
as well as in patients with regional lymph node metastasis
(N1) compared to those without regional lymph node in-
volvement (N0) (P = 0.0017; Figure 2B). Moreover, both
miR-32 and miR-182 were overexpressed in PCa compared
to matched normal prostate tissues (P < 0.0001; Additional
file 3: Figure S4).
Correlation analysis for miRNAs expression showed
that miR-375 was significantly co-expressed with miR-32
and miR-182 (r = 0.36 and r = 0.60, respectively; Table 3
and Figure 3).MiR-375 expression in prostate cell lines
PCa cell line 22Rv1 depicted the highest miR-375 ex-
pression levels, whereas the lowest were found in PC-3
cells (Figure 4). In RWPE-1 cells, miR-375 expression
levels were lower than those of any PCa cell line, mim-
icking the results of PCa and MNPT tissues. Thus, those
cell lines were selected for subsequent functional experi-
ments of miR-375 downregulation (22Rv1) or forced ex-
pression (PC-3 and RPWE-1).
Phenotypic impact of miR-375 forced expression in PC-3
cells and RWPE-1 cells
At 72 h after transfection, miR-375 expression levels were
increased 56,000 and 8,000 times in PC-3 and RPWE-1
cells, respectively (P < 0.001 for both) (Figures 5A and 6A).
PC-3 cells’ viability was significantly reduced at 48 h (39%,
P < 0.01) and 72 h (60.5%, P < 0.001) (Figure 5B). Moreover,
72 h after transfection, apoptosis levels were significantly
increased (more than threefold (P < 0.001), Figure 5C).
Figure 2 Expression of has-mir-375 is increased in prostate cancer and associates with lymph node stage in patients from TCGA. (A) miR-375
expression (TCGA miRNAseq RPKM level 3 value) was evaluated in 50 tumor and matched normal samples of prostate adenocarcinoma patients from
TCGA. All tumor samples presented overexpression comparing to their matched normal samples (***P < 0.0001). (B) The expression of hsa-mir-375
(TCGA miRNAseq RPKM level 3 value) was assessed in 177 prostate adenocarcinoma patients from TCGA with lymph node stage information available.
Patients in the N1 lymph node stage presented significantly higher expression of hsa-mir-375 than patients in the N0 stage.
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following miR-375 forced expression and a maximum of
52% reduction was observed in transfected cells (P < 0.01)
(Figure 5D and Additional file 4: Figure S2). In transfected
RWPE-1 cells, and despite a significant increase in miR-375Table 3 Validation of the correlation between hsa-mir-375
and identified upregulated microRNAs in prostate
adenocarcinoma samples from TCGA dataset [40]
microRNA Spearman’s correlation P value
hsa-mir-449a 0.27351 <0.0001
hsa-mir-32 0.36431 <0.0001
hsa-mir-548C N/A
hsa-mir-562 N/A
hsa-mir-103-1-AS N/A
hsa-mir-103-2-as N/A
hsa-mir-512-1 0.13177 0.01729
hsa-mir-512-2 0.05064 0.36211
hsa-mir-200C 0.59926 <0.0001
hsa-mir-147B 0.12526 0.02370
hsa-mir-770 −0.09100 0.10099
hsa-mir-518C −0.01563 0.77866
hsa-mir-517B −0.03261 0.55740
hsa-mir-182 0.60472 <0.0001
hsa-mir-615 0.39231 <0.0001
hsa-mir-496 −0.23667 <0.0001
hsa-mir-1200 N/A
hsa-mir-551a −0.00138 0.98014
N/A, not applicable.levels, no significant alterations in cell viability and apop-
tosis were apparent (Figure 6B, C), suggesting that miR-375
deregulation is mostly relevant in the context of malignant
prostate cell.Phenotypic impact of miR-375 downregulation in 22Rv1
cells
Expression levels of miR-375 were decreased by 68% 72 h
after transfection (P < 0.001; Figure 7A) and this was associ-
ated with significantly reduced cell viability (P < 0.01). At
this time point, viable cells reached only 17% (Figure 7B)
and apoptosis increased by 30% (P < 0.01) in 22Rv1-
transfected cells (Figure 7C). Because this cell line displays
low invasive ability, invasion assay was not performed.Putative miR-375 targets
The search for putative miR-375 targets comprised expres-
sion analysis of 61 genes implicated in some of the most
important cellular pathways deregulated in cancer. Thus,
expression profiles of PC-3 transfected (pre-miR-375) and
22Rv1 transfected (anti-miR-375) cells were compared to
its respective controls (Additional file 5: Figure S3). In
22Rv1 cell with miR-375 downregulation, RB1 was upregu-
lated, whereas in miR-375-overexpressing PC-3 cells,
CCND2 was downregulated (P < 0.001 for both). These
findings were validated in tissue samples as RB1 transcript
levels were significantly increase and CCND2 expression
levels were significantly decreased in primary PCa com-
pared to MNPT (Figure 8). Furthermore, gene ontology
enrichment analysis disclosed that genes involved in cell
cycle regulation were those more frequently deregulated in
Figure 3 miR-375 is significantly co-expressed with (A) miR-32 and (B) miR-182 in prostate cancer patients from TCGA (r calculated by
Spearman’s correlations).
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for miR-375 in PCa.
miR-375 directly targets CCND2
In silico analysis identified a miR-375 potential binding site
at CCND2 3′untranslated region (UTR). Moreover, analysis
of TCGA data disclosed a statistically significant negative
correlation between miR-375 and CCND2 expression in
PCa tissues (Spearman’s correlation, r =−0.57, P < 0.0001).
Luciferase assay was performed in PC-3 cells to determine
whether miR-375 might regulate CCND2 transcription
levels. In CCND2 3′UTR vector and pre-miR-375 co-
transfected PC-3 cells, a sixfold increase in miR-375 expres-
sion levels was apparent at 72 h (Figure 10A), whereas
CCND2 3′UTR luciferase activity was 37% reduced, at 48 h
(P < 0.01), and 71% at 72 h (P < 0.001) after transfection
(Figure 10B).
Discussion
Prostate cancer remains a major challenge, mostly due
to insufficient knowledge about the factors determiningFigure 4 miR-375 expression levels in prostate cell lines. Results are
displayed after normalization to RWPE-1.its onset and progression [14]. Because epigenetic alter-
ations play an important role in prostate carcinogenesis
and owing to the relative shortage of validated data on
miRNA altered expression in PCa, we aimed to identify
and validate miRNAs upregulated in this malignancy.
Furthermore, its impact on malignant cell phenotype
was assessed and putative target genes were identified.
The strategy used in our study is similar to that of some
previous publications on this subject [15,16].
Results of the miRNA expression array showed that, in
PCa, miRNAs are mostly downregulated, whereas only a
minor subset is overexpressed, confirming previous re-
ports [13]. Because expression array data may be biased
owing to the (usually) small number of samples assessed
[17], we decided to validate the miRs overexpressed in
the array, and not previously associated with PCa, in two
large and independent datasets. Importantly, miR-182
and miR-375 overexpression was confirmed in the valid-
ation datasets. However, miR-32 overexpression was not
validated and expression of other miRNAs was found
to be minimal or absent. These observations further
emphasize the need of validation studies following ex-
pression array experiments, as well as possible tech-
nical limitations for miRNA analysis.
Because a report on miR-182 overexpression in PCa
was published during the execution of this study [18],
we then proceeded with miR-375 for further analysis.
Although MiR-375 expression levels in body fluids had
been previously proposed as diagnostic and prognostic
PCa biomarkers [19-21], its biological role in prostate
carcinogenesis has not been investigated before. We
found that, in PCa tissues, miR-375 expression was
higher than in normal prostate tissues, paralleling the
results of body fluids analysis [19-21]. Furthermore,
higher expression levels associated with higher Gleason
score and more advanced pathological stage, two clini-
copathological parameters that entail unfavorable prog-
nosis. These observations were further validated in an
independent dataset through meta-analysis of TCGA
Figure 5 Forced expression of miR-375 in PC-3. (A) Relative expression of miR-375 (normalized to miR-NC), (B) number of viable cells, (C) relative
apoptosis levels (normalized to miR-NC), and (D) relative invasion (normalized to miR-NC). (B, C, D) Data shown as the median of three
independent experiments and range performed in triplicate (***P < 0.001; **P < 0.01).
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sues. Interestingly, an association of higher miR-375 ex-
pression levels and regional lymph node metastases
was depicted, providing additional confirmation of our
results. Although miR-32 expression levels did not dif-
fer between PCa and MNPT in our dataset, the larger
number of samples available at the TCGA demon-
strated increased expression PCa compared to matched
normal prostate tissues. It is noteworthy that normal
samples differ not only in number (15 vs. 50) but also
in its nature as we used MNPT from patients not carry-
ing PCa whereas normal prostate tissues from TCGA
correspond to matched samples from PCa patients.
Although this and other studies [19-21] implicate
miR-375 upregulation in PCa, miR-375 has been mostly
considered a tumor suppressor, namely in gastric, head
and neck, pancreatic, and hepatocellular cancers [22-25].
Indeed, in gastric cancer, miR-375 forced expression in-
creased apoptosis and reduced of cell viability in vitro
[25], and janus kinase 2 (JAK2) was identified as a directtarget [26]. It should be emphasized, however, that miR-
375-altered expression reports are mostly based in
microarray or validation platform analysis attempts to
discriminate different tumor subgroups according to
miRNAs expression, seldom providing biological clues
to the role of miR-375 in cancer [19,20,27-29].
Expression analysis results of miR-375 in prostate cells
lines parallel those of primary tissues, as the lowest
levels were found in RWPE-1, a benign prostate cell line.
However, whereas 22Rv1 cells displayed high expression
levels, PC-3 cells disclosed significantly lower levels.
These findings provided a unique opportunity to
evaluate the biological role of miR-375 in PCa cells,
using two opposing, yet complementary strategies. In-
triguingly, both anti-miR-375 transfection in 22Rv1
cells (causing 68% reduction in miR-375 expression
levels) and forced miR-375 expression in PC-3 cells attenu-
ated the malignant phenotype, whereas in RPWE-1 cells,
forced miR-375 expression did not cause significant pheno-
typic alterations. Thus, while in 22Rv1 cells an oncogenic
Figure 6 Forced expression of miR-375 in RWPE-1. (A) Relative expression of miR-375 (normalized to miR-NC), (B) number of viable cells,
and (C) relative apoptosis levels (normalized to miR-NC). (B, C) Data shown as the median and range of three independent experiments
performed in triplicates. ***P < 0.001.
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is implied for PC-3 cells. Considering that miRNAs might
play an oncogenic or tumor-suppressive role depending on
the cellular context in different tumors [19,22], this obser-
vation would not be surprising, except for the fact that it
occurred in the same tumor model. However, due to the
widely acknowledged heterogeneity of PCa, it may be rea-
sonable to assume that in different prostate cancers (herein
represented by different cell lines) miR-375 could play an-
tagonistic roles.
Considering the potential dual role of miR-375 in PCa,
the expression of 61 cancer-related genes, involved in crit-
ical cellular pathways, was assessed in PC-3 and 22Rv1
transfected cells. The panel of altered genes was, indeed,
different in each cell line, as it would be expected from the
results of the phenotypic assays and the baseline expression
levels of miR-375. These results might also be explained by
the acknowledged ‘promiscuity’ of miRNAs, as a single
miRNA may target several different gene transcripts in
a time- and model-dependent manner [10,30]. In theexpression analysis, retinoblastoma 1 (RB1) and cyclin D2
(CCND2) surfaced as the most deregulated genes in each
cell line. Remarkably, CCND2 expression was found to be
decreased in primary PCa samples, consistent with a puta-
tive target of miR-375 (which is overexpressed in those
samples), whereas RB1 was overexpressed in the same set
of primary tumors. The former result is in line with previ-
ous reports on CCND2 downregulation in PCa [31,32]
whereas the latter contradicts previous observations con-
cerning RB1 downregulation in PCa [33]. However, it
should be emphasized that in addition to miR-375, other
epigenetic and/or genetic mechanisms, eventually more
relevant in vivo, might be involved in RB1 expression regu-
lation in PCa. Furthermore, the luciferase assay confirmed
that CCND2 is a target of miR-375 as CCND2 transcript
levels were significantly reduced after miR-375 forced ex-
pression. Interestingly, CCND2 is a key element in cell cycle
regulation, and this pathway was found as the most relevant
in which miR-375 was implicated, in gene ontology enrich-
ment analysis of both transfected cell lines. It should be
Figure 7 Inhibition of miR-375 in 22Rv1. (A) Relative expression of miR-375 (normalized to miR-NC), (B) number of viable cells, and (C) relative
apoptosis levels (normalized to miR-NC). (B, C) Data shown as the median and range of three independent experiments performed in triplicates
(***P < 0.001; **P < 0.01).
Figure 8 Expression levels of potential miR-375 targets for array validation (A) RB1 and (B) CCND2 (**P < 0.01).
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Figure 9 GO enrichment analysis: pathways (A) downregulated in PC-3 and (B) upregulated in 22Rv1 transfected cells.
Figure 10 Luciferase reporter assay for the 3′UTR of CCND2 in PC-3 cells. (A) Transfection of pre-miR-375 resulted in an increase of miR-375 upon
transfection. (B) Luciferase activity was measured upon 48 and 72 h upon co-transfection of control vector with miR-NC and CCND2 with pre-miR-375. Data
shown as the median and range of three independent experiments performed in triplicates (***P< 0.001; **P< 0.01).
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been associated with aberrant promoter methylation [31]
and, thus, different epigenetic mechanisms may act in con-
cert to accomplish CCND2 silencing in PCa.
Our results thus suggest that miR-375 plays a dual
role in PCa, acting either as an oncomiR or a tumor-
suppressor miRNA, depending on the cellular context.
It is noteworthy that PCa cell lines with the highest
miR-375 expression levels are androgen-responsive (22Rv1
and LNCaP), whereas androgen-independent (DU145 and
PC-3) cells display the lowest levels. Strikingly, these results
are in line with previous reports that associate DNMT
activity, promoter methylation of miR-375 and androgens
[34]. Interestingly, although derived from metastasis, 22Rv1
and LNCaP cell lines display the miR-375 expression profile
typical of primary PCa from both series analyzed, and these
are also androgen responsive as they represent clinically
localized, androgen-ablation therapy-naïve tumors. Thus,
the cellular context in which miR-375 may act as oncomiR
or tumor suppressor is likely to be conditioned by androgen
receptor regulation. Examples of miRNAs that may act as
tumor suppressors or oncomiRs, depending on the tumor
model, are acknowledged (for example, cluster miR-191/
425 in breast cancer depending on estrogen status) [35].
However, this seems to be a previously unrecognized event
in which a miRNA may have that dual role in the same
tumor model, depending on the stage of tumor progression
and hormonal environment. It is tempting to speculate
whether in the same tumor, along its progression, miR-375
may act initially as an oncomiR and later as a tumor sup-
pressor, targeting different genes as disease progresses. The
mechanisms underlying this putative alteration remain elu-
sive but it could derive from the significant alteration of the
gene expression landscape of PCa cells along disease pro-
gression [36].
Conclusions
In conclusion, our data provides further insight into miR-
NAs overexpression in PCa, suggesting that miR-375
upregulation might be act as oncomiR at the initial steps of
prostate carcinogenesis, a role that could be impaired as
PCa progresses, probably due to the cumulative genetic
and epigenetic alterations endured by cancer cells. We pro-
vide evidence that miR-375 deregulation disturbs several
critical cellular pathways, especially cell cycle regulation,
eventually through CCND2 targeting, which may, at the
least partially, explain the frequent downregulation of
CCND2 in primary PCa.
Methods
Patients and sample collection
Primary tumors from 119 patients harboring clinically
localized prostate adenocarcinoma were prospectively col-
lected after diagnosis and primary treatment with radicalprostatectomy at Portuguese Oncology Institute, Porto,
Portugal. A set of 15 MNPTs was collected from prostatic
peripheral zone of bladder cancer patients submitted to
cystoprostatectomy. All tissue specimens were promptly
frozen immediately after surgery. Upon histological con-
firmation of tumor or normal prostate tissue, fresh-frozen
tissue fragments were trimmed to enhance yield of tar-
get cells (>70%). Histological slides from formalin-fixed
paraffin-embedded tissue fragments were also routinely
obtained from the surgical specimens and assessed for
Gleason score and TNM stage. Relevant clinical data
was collected from clinical charts. Informed consent
was obtained from all participants, according to institu-
tional regulations. This study was approved by the
institutional review board [Comissão de Ética para a
Saúde-(CES-IPOPFG-EPE 205/2013)] of Portuguese
Oncology Institute - Porto, Portugal.
Cell culture
Human PCa cell lines available in our lab (LNCaP,
22Rv1, DU145 and PC-3) and a non-malignant prostate
cell line (RWPE-1, kindly provided by Prof. Margarida
Fardilha, University of Aveiro, Portugal) were used in
this study. All cell lines were cultured using recom-
mended medium supplemented with 10% of fetal bovine
serum and 1% of penicillin-streptomycin (FBS; GIBCO,
Invitrogen, Carlsbad, CA, USA) and maintained at 37°C
and 5% CO2 in a humidified chamber. All cell lines were
routinely tested for contamination by Mycoplasma spp.
using a specific multiplex PCR (PCR Mycoplasma Detec-
tion Set, Clontech Laboratories Inc., Mountain View,
CA, USA).
Total RNA extraction
Total RNA from clinical samples and cell lines was
obtained by suspension in TRIzol® reagent (Invitrogen,
Carlsbad, CA, USA) and, after adding chloroform, total
RNA was purified from the aqueous phase of TRIzol® ex-
tract using PureLink™ RNA Mini Kit (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s recommendations.
RNA concentration, purity, and integrity of samples were
determined on a Nanodrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA) and
electrophoresis.
MicroRNAs global expression
Global miRNAs expression was assessed in ten PCa and
four MNPT using microRNA Ready-to-Use PCR Human
Panel (I + II) v2.0 (Exiqon, Vedbaek, Denmark), consisting
of 739 miRNAs in total. RNA samples were submitted to
cDNA synthesis using miRCURY LNA™ Universal RT
microRNA PCR (Exiqon, Vedbaek, Denmark) following
manufacturer’s instructions. Briefly, for each sample, 4 μL
of 5× reaction buffer, 9-μL nuclease-free water, 2 μL of
Costa-Pinheiro et al. Clinical Epigenetics  (2015) 7:42 Page 11 of 14enzyme mix, 1 μL of synthetic spike in, and 4 μL of previ-
ously concentration-adjusted RNA. Tubes were then vor-
texed gently, and reverse transcription was performed in
Veriti® Thermal Cycler (Applied Biosystems, Foster City,
CA, USA). Protocol consisted of incubation for 60 min at
42°C, followed by 5 min at 95°C. Global expression was
performed in a LightCycler 480 Instrument (Roche
Diagnostics, Manheim, Germany) according to the
manufacturer’s conditions. Data was analyzed using GenEX
software (MultiD Analyses AB, Göteburg, Sweden). Then,
data were analyzed using the comparative Ct method
[37]. Median value of reference genes was used for
normalization, and miRNAs with fold change higher
than 1.5 were classified as overexpressed in PCa com-
pared to MNPT.
Validation of microRNAs expression
cDNA was synthesized from 119 PCa, 15 MNPT and 5
prostate cell lines, using miRCURY LNA™ Universal RT
microRNA PCR (Exiqon, Vedbaek, Denmark), following
the manufacturer’s instructions, as described above. Sam-
ples were then eluted 80× in nuclease-free water. MiRNAs’
levels were evaluated using specific primers (microRNA
LNA™ PCR primer set, Exiqon, Vedbaek, Denmark) accord-
ing to the manufacturer’s recommendations. In each well,
4 μL of diluted cDNA were mixed with 1 μL of specific
miRNAs qPCR primers (Exiqon, Vedbaek, Denmark), 2 μL
of ROX reference dye (Invitrogen, Carlsbad, CA, USA) and
5 μL of SYBR® Green Master mix (Exiqon, Vedbaek,
Denmark). Protocol consisted in a denaturation step
at 95°C for 10 min, followed by 40 amplification cycles
at 95°C for 10 s and 60°C for 1 min. As previously
mentioned, melting curve analysis was also performed
at the end of the procedure according to instrument’s
manufacturer recommendations. Each 96-well plate
included multiple non-template controls and serial di-
lutions (10×) of cDNA obtained from human prostate
RNA (Ambion, Invitrogen, Carlsbad, CA, USA) was
used to construct a standard curve for each plate. All
experiments were run in triplicates in a 7500 Sequence
Detection System (Applied Biosystems, Foster City,
CA, USA). Considering the results from global analysis, it
was decided to use the reference gene with less variation
(miR-423-5p) among samples for normalization of valid-
ation data. Relative expression of miRNAs was determined
as target gene mean quantity/reference gene mean quantity.
Values were then multiplied by 1,000 for easier tabulation.
MicroRNAs transient transfection
miR-375 was transiently transfected in PC-3 and RWPE-1
cells with a Pre-miR™ miRNA precursor (pre-miR-375,
PM10327, Applied Biosystems, Foster City, CA, USA) and
an Anti-miR™ miRNA inhibitor (anti-miR-375, AM10327,
Applied Biosystems, Foster City, CA, USA) was transfectedfor 22Rv1 cells. A miRNA negative control was used as
control in all experiments (miR-NC, AM17010, Applied
Biosystems, Foster City, CA, USA). Cells were seeded under
standard conditions in six-well and 96-well plates for 24 h
before transfection, reaching 30% to 50% confluence. In
these experiments, pre-miR-375, anti-miR-375, and
miR-NC concentration was 50nM. Oligofectamine™ re-
agent (Invitrogen, Carlsbad, CA, USA) was used under
conditions indicated by the manufacturer. Cells were
then incubated at 37°C and 5% CO2 in a humidified
chamber for 72 h upon transfection. At 72 h, forced ex-
pression or silencing of miR-375 were confirmed by
RT-qPCR.
Cell viability assay
To evaluate the impact of in vitro transfection of miR-375
in PCaer cell lines, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT; Sigma-Aldrich, Schnelldorf,
Germany) assay was performed in 96-well plates. Briefly,
cells were incubated with 10% MTT at 5 mg/mL in a
humidified chamber for 24, 48, and 72 h after transfection.
Reaction was stopped by removal of MTT and addition of
100 μL DMSO (Sigma-Aldrich, Schnelldorf, Germany) per
well. Finally, plates were shaken for 15 min for complete
dissolution. Absorbance levels were measured using a mi-
croplate reader (Fluostar Omega, BMG Labtech, Offenburg,
Germany) at 540 nm with background deduction at
630 nm. Number of viable cells was obtained using the fol-
lowing formula: (OD experiment ×Mean number of cells
at 0 h)/Mean OD at 0 h. Three biologically independent ex-
periments were performed, comprising methodological
triplicates for each experiment.
Apoptosis assay
Apoptosis was assessed using the APOPercentage™ kit
(Biocolor Ltd., Belfast, Northern Ireland, UK). Cell lines
were seeded under the same conditions as described for
MTT assay and, after 72 h incubation, apoptosis assay
was performed according to the manufacturer’s instruc-
tions. Quantification of apoptosis was achieved by meas-
uring the optical density of the released dye at 550 nm
with background deduction at 620 nm using a FLUOstar
Omega microplate reader. To normalize the OD ob-
tained for the apoptosis assays relatively to cell number,
OD of cell viability assay at 72 h was used. Results were
expressed as ratio of transfected cells OD to miR-NC
OD (set as 100%).
Invasion assay
Invasion ability of PC-3 transfected cells was analyzed using
BD Biocoat™ Matrigel Invasion Chambers (BD Biosciences,
Franklin Lakes, NJ, USA) according to the manufacturer’s
protocol. Briefly, cells were seeded and then transfected in
six-well plates. After 48 h of transfection, cells were
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Matrigel inserts and allowed to invade for 24 h at 37°C and
5% CO2 in a humidified chamber. Medium with serum was
used as chemoattractant. Then, non-invasive cells were re-
moved from the top of the membranes and cells that in-
vaded were fixed with methanol and stained with DAPI.
Invasive cells were manually counted in a fluorescence
microscope, and results were displayed as a percentage of
cells that crossed the membrane (invading cells) relative to
miR-NC.
Identification of potential miR-375 target genes
To determine whether miR-375 was implicated in regula-
tion of selected genes involved in cell cycle, apoptosis,
DNA repair, mTOR, or MAPK/ERK pathways, a custom
array panel (Roche Applied Science, Manheim, Germany)
was designed for quantification of selected gene expression.
Total RNA was extracted from all cell lines using TRIzol®
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions and cDNA synthesis was performed
using Transcriptor High Fidelity cDNA Synthesis Kit
(Roche, Manheim, Germany) according to the manufac-
turer’s instructions. Expression levels were determined by
real-time PCR in a LightCycler 480 (Roche Diagnostics,
Manheim, Germany) and the amount of mRNA was
normalized using GUSB, TFRC, and 18S as endogenous
controls. The comparative Ct method [37] was used to cal-
culate fold-difference in gene expression between mir-375
transfected cells and respective miR-NC.
Gene ontology enrichment analysis
Gene ontology enrichment (GOE) analysis was per-
formed to ascertain which biological processes are regu-
lated by miR-375 in PCa cell lines. AmiGO database [38]
was used, and statistical analysis was performed using R
program based on hypergeometric distribution followed
by Fisher’s exact test [39].
Expression of potential target genes in clinical samples
Following gene selection, mRNA levels were confirmed in
the same group of tissue samples previously indicated.
A total of 300 ng was reverse transcribed and amplified
using TransPlex® Whole Transcriptome Amplification Kit
(Sigma-Aldrich®, Schnelldorf, Germany) with subsequent
purification using QIAquick® PCR Purification Kit
(QIAGEN, Hilden, Germany), according to the manu-
facturer’s instructions. Expression levels were evaluated
using TaqMan® Gene Expression Assays (Applied Bio-
systems, Foster City, CA, USA), and GUSB was used as
a reference gene for normalization, according to the
formula: Relative expression = (Target gene mean quantity/
Reference gene mean quantity). Ratios were then multiplied
by 1,000 for easier tabulation. Each plate included multiple
non-template controls and serial dilutions (10×) of a cDNAobtained from human prostate RNA (Ambion) were used
to construct a standard curve for each plate. All experi-
ments were run in triplicates.
Luciferase assay
A reporter construct containing a binding site at CCND2
3′UTR for miR-375 (GeneCopoeia, Rockville, MD, USA)
was introduced into PC-3 cells using Turbofectin 8.0
transfection reagent (Origene, Rockville, MD, USA). A
vector without CCND2 3′UTR (GeneCopoeia) was used
as experiment control. Vectors were co-transfected
along with pre-miR-375 as described. Luciferase activity
was assessed with the Secrete-Pair™ Dual Luminescence
Assay Kit (GeneCopoeia, Rockville, MD, USA) according
to the manufacturer’s instructions. Experiments were
performed in triplicates at 48 and 72 h following co-
transfection. At 72 h, miR-375 levels were measured by
RT-qPCR to confirm its forced or silenced expression.
TCGA data meta-analysis in prostate cancer patients
TCGA was used to obtain data on miRNA expression
and clinical information, when available, from PCa and
matched normal tissue samples [40]. All miRNA ex-
pression data from samples hybridized by the University
of North Carolina, Lineberger Comprehensive Cancer
Center, using Illumina HiSeq 2000 miRNA Sequencing,
were downloaded from TCGA data matrix (http://tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp). This dataset in-
cluded 326 PCa and 50 matched normal patient samples.
To prevent duplicates, when there was more than one
portion per patient, median values were used. The pro-
vided value was pre-processed and normalized according
to ‘level 3’ specifications of TCGA (see http://cancergen-
ome.nih.gov/ for details). Clinical data of each patient
was provided by the Biospecimen Core Resources
(BCRs). This data is available for download through
TCGA data matrix (http://tcga-data.nci.nih.gov/tcga/data
AccessMatrix.htm).
Statistical analysis
The Shapiro-Wilk’s W test allowed for the examination of
the appropriateness of a normal distribution assumption
for each of the parameters (data not shown). Comparisons
between two groups were then performed using non-
parametric Mann–Whitney U-test. P values were consid-
ered statistically significant if lower than 0.05.
Correlation between miRNAs’ expression was measured
by the Spearman’s correlation coefficient (r). Differences in
miR-375 expression between N0 and N1 lymph node stage
groups were assessed by Student’s t-test.
Statistical analysis was performed SPSS 20.0 for Mac
(IBM-SPSS Inc., Chicago, IL, USA), and graphs were
built using GraphPad Prism 5.0 software for Mac
(GraphPad Software Inc., La Jolla, CA, USA).
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